
Cinclus Pharma Q1 - Focus on upcoming pivotal study

Redeye provides a research update following the Q1 report published by Cinclus earlier today. The report did not include any major surprises and was mostly in line with our expectations. All eyes are now on the forthcoming phase III study, set to be initiated in Q3 2025e.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cinclus Pharma Q1 - Focus on upcoming pivotal study](#)